CelLBxHealth PLC - Issue of Share Options
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of

CelLBxHealth plc
("CelLBxHealth" or the "Company")
Issue of Share Options
Share Options are issued to align the interest of employees with shareholders and help motivate, reward and retain them. The allocation of Share Options approved by the Nominations/Remuneration Committee takes into account the significant contribution from the senior management team and wider staff to the task of delivering against the revised business strategy, and, in particular, to converting the commercial pipeline into sustainable revenue growth. This, in turn, would be expected to deliver increased shareholder value.
Following the issue of these options, the Company will have outstanding options over a total of up to 55,845,000 Ordinary Shares, representing approximately 4.9% of its issued and to be issued share capital.
The exercise price for the Share Options is
All of these Share Options have performance conditions as set out below:
· Time-based vesting: One-third (1/3) of the Share Options will vest on the first anniversary of the grant date. The remaining time-based options will then vest in equal quarterly instalments of one-twelfth (1/12) over the following two years.
· Performance-based vesting: The final portion of the Share Options (those scheduled to vest during quarters 7 to 12 after the grant date) will only vest if, in addition to the employee remaining continuously employed, the Company's share price closes at or above 2.5p on any 10 out of 20 consecutive trading days at any point before the end of the three-year period.
For further information:
|
CelLBxHealth plc |
via Walbrook PR |
|
|
|
|
Cavendish (NOMAD and Broker) |
+44 (0)20 7220 0500
|
|
|
|
|
Walbrook PR (Investor and Media Relations) |
Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
About CelLBxHealth plc
CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial focus span three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant
For more information, visit https://cellbxhealth.com/
Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities ("PDMR") and persons closely associated with them ("PCA")
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail in respect of the transaction as described above.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||
|
a) |
Name |
|
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Chief of Staff |
|||
|
b) |
Initial notification /Amendment |
Initial notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
CelLBxHealth Plc |
|||
|
b) |
LEI |
213800BY11K6W3NMS374 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of |
|||
|
|
|
||||
|
Identification code |
GB0034330679 |
||||
|
|
|
||||
|
b) |
Nature of the transaction |
Options over ordinary shares of |
|||
|
c) |
Price(s) and volume(s) |
|
|||
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
|
Up to 11,400,000 dependent on share price performance |
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
n/a |
||||
|
|
|
||||
|
- Price |
n/a |
||||
|
|
|
||||
|
e) |
Date of the transaction |
|
|||
|
f) |
Place of the transaction |
Off Market |
|||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE